Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
This article was originally published in The Tan Sheet
Executive Summary
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture